View Clinical Trial (Medical Research Study)

Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus - NCT00573911-55905(Clinical Trial 195199)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Rochester
State:  
MN
Zip Code: 55905
Conditions: Barrett's Esophagus - GERD
Purpose: Patients with Barrett's Esophagus are known to have excessive distal esophageal acid exposure comparable to patients with erosive esophagitis. A significant proportion of patients with BE who are not symptomatic on treatment continue to have persistent acid reflux. High dose esomeprazole is able to control acid reflux in patients with BE. The effect of acid reflux on Barrett's esophagus stroma is currently unknown. It is our hypothesis that stromal fibroblast activation in Barrett's esophagus is influenced by acid reflux. The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.
Study summary: We will conduct a prospective cohort study to assess the degree of stromal activation in patients with LSBE (without dysplasia) who have adequate and inadequate control of acid reflux in the distal esophagus. The study will be conducted in two phases. Phase 1 (Pilot): 20 patients with LSBE without dysplasia will undergo endoscopy with biopsies and a 24 hour pH study on treatment. Patients will then be divided into 2 groups: - Group A (GER): Those with ongoing acid reflux (characterized by either presence of esophagitis [LA classification B,C or D1] on endoscopy, and/or a positive pH study on treatment defined using standard criteria) - Group B (NGER): Those with controlled acid reflux (negative endoscopy and pH study on treatment). Stromal markers that will be assessed and compared between the 2 groups will include: presence of activated myofibroblasts (detected by immunohistochemistry for vimentin and smooth muscle actin).
Criteria: Inclusion Criteria: - Prior histological demonstration of Barrett's esophagus that is endoscopically visible; length of visible segment >/= 1 cms - Absence of dysplasia on prior biopsies - Laboratory studies: - Prothrombin time (INR) < 1.5 - Hemoglobin > 8.0 gm/dL - Ability to provide informed consent Exclusion Criteria: - Eastern Cooperative Oncology Group performance status 3 or 4 - Inability to tolerate endoscopic procedures - Pregnancy: Females of child-bearing age will be screened with pregnancy test. Although none of the procedures in the study are contraindicated in pregnancy, sedation used in endoscopy can be contraindicated in early pregnancy - Prior esophageal surgery, or cancer
Study is available at: Mayo Clinic
Rochester, MN 55905
United States

Primary Contact:
Kelly T. Dunagan
Phone: 507-255-8692
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.